No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

The study, published Jan. 20 in The Lancet Infectious Diseases, found the vaccine to be 78% effective against RSV infection, 79% effective against emergency department and urgent care visits and 80% ...

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Marc Watkins, M.D., chief medical officer at Kroger Health, discusses RSV and how people can protect themselves and their ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

New York Amsterdam News | Word In Black (WIB) - With the triad of respiratory viruses present in our day-to-day, it ...

Beyond sidestepping people’s fear of needles, these vaccines would also make it easier to store and distribute ahead of ...